PL Developments (PLD) has brought its contract services division, Avéma Pharma Solutions, under the PLD brand as PLD Pharma Services. With this move, PLD is consolidating its divisions with a unified identity that reflects the company’s commitment to developing and manufacturing high quality, liquid and solid dose OTC and Rx products to its customers.
As a full service CDMO, Avéma has built a strong reputation for its full range of product development capabilities – providing integrated support from concept through development, pilot production, full scale manufacturing, and regulatory approvals. In the contract manufacturing space, Avéma has consistently leveraged PLD's extensive library of base formulations and drawn upon the company's decades of expertise with a wide range of APIs in both solid and liquid dosage forms.
By bringing Avéma’s expertise under the PLD brand, the company is creating a stronger, more integrated presence in the CDMO market. This transition ensures that our clients experience a seamless, consistent partnership from a single trusted brand.
The rebranding comes at a time when PLD has invested in several infrastructure upgrades including:
- New Analytical and R&D labs,
- A pharmaceutical grade gummy and gum manufacturing facility, and
- Increased production capacity for liquid bottle filling.
PLD also recently received FDA approval for its Omeprazole Magnesium Tablet, a product comparable to Prilosec® OTC. The product will be manufactured at PLD's facility in Miami, FL, making PLD the only provider of Omeprazole OTC produced in the United States. This achievement underscores the company's extensive capabilities to develop, manufacture, and commercialize the most complex products offered in the US consumer healthcare market.